Dr. Sun Discusses the Debate Between Radiation and Chemotherapy in GEJ Cancers

Video

Weijing Sun, MD, gastrointestinal oncologist at the University of Kansas School of Medicine, discusses the debate between the use of radiation and chemotherapy in patients with locally advanced gastroesophageal junction (GEJ) adenocarcinoma.

Weijing Sun, MD, gastrointestinal oncologist at the University of Kansas School of Medicine, discusses the debate between the use of radiation and chemotherapy in patients with locally advanced gastroesophageal junction (GEJ) adenocarcinoma.

There are 2 preoperative therapeutic approaches for patients with locally advanced GEJ cancer, explains Sun—one includes radiation therapy and one does not. In the FLOT study, investigators explored a regimen comprised of fluorouracil, leucovorin, oxaliplatin, and docetaxel without radiation. In the CROSS study, investigators looked at the combination of carboplatin and paclitaxel with radiation. Although both are suitable options for patients, explains Sun, their respective roles are controversial.

Radiation is a local treatment as opposed to chemotherapy, which is a systemic therapy. They are both effective ways to shrink a tumor prior to resection, says Sun, but in terms of managing micrometastatic disease, radiation is not considered to be as effective as chemotherapy, as it is a local treatment. There are 2 parameters by which treatment effectiveness is assessed, says Sun. One is response rate, while the other is disease-free survival after surgery. In terms of response rate, both modalities demonstrate similar efficacy, but in terms of disease-free survival, the roles of radiation and chemotherapy are less clear, explains Sun.

Related Videos
Video 10 - "Monitoring and AE Management Strategies with Fruquintinib in CRC"
Video 9 - "FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC"
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles